|
24 Feb 2020 |
ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis
|
|
21 Feb 2020 |
NoNO Inc. Reports Groundbreaking Results from the Phase 3 ESCAPE-NA1 Study of the Peptide, Nerinetide, in Acute Ischemic Stroke
|
|
21 Feb 2020 |
Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
|
|
20 Feb 2020 |
Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643
|
|
12 Feb 2020 |
Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement to Develop Broad-spectrum Enzyme Replacement for Malabsorption Syndromes
|
|
11 Feb 2020 |
Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium™ 2020
|
|
11 Feb 2020 |
Seurat Therapeutics Announces Novel Mechanisms from Rat Migraine Model of Intranasal Insulin-like Growth Factor-1
|
|
07 Feb 2020 |
Catalyst Biosciences Presents Positive Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) and Marzeptacog alfa (activated) (MarzAA) Programs at the 13th Annual EAHAD Congress
|
|
03 Feb 2020 |
AntiCancer Inc. to Target Its Oral Recombinant Methioninase Against 2019-nCoV Coronavirus
|
|
02 Feb 2020 |
CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes
|
|
02 Feb 2020 |
Rybelsus® (oral semaglutide) recommended for approval for the treatment of adults with type 2 diabetes by the European regulatory authorities
|
|
31 Jan 2020 |
Rani Therapeutics Announces Positive Phase I Study Results of Oral Octreotide using RaniPill™
|
|
30 Jan 2020 |
Theraly Fibrosis Awarded $3.9 Million SBIR Phase II Grant to Support Development of TLY012 for Chronic Pancreatitis
|
|
30 Jan 2020 |
Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency
|
|
28 Jan 2020 |
Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer’s Disease
|
|
27 Jan 2020 |
Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow’s Feet Lines Published in Dermatologic Surgery
|
|
27 Jan 2020 |
NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase 1b/2a Study of Hyleukin-7™ (NT-I7) and KEYTRUDA® (Pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors
|
|
27 Jan 2020 |
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
|
|
23 Jan 2020 |
Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
|
|
22 Jan 2020 |
Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial
|
|
21 Jan 2020 |
Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272
|
|
17 Jan 2020 |
Rybelsus label updated with additional information from the PIONEER 6 CV outcomes trial
|
|
13 Jan 2020 |
Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
|
|
13 Jan 2020 |
MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate
|
|
12 Jan 2020 |
Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement
|
